Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

Gut Feeling in AKI: The Long Arm of Short–Chain Fatty Acids

Ian R. Barrows, Ali Ramezani and Dominic S. Raj
JASN August 2015, 26 (8) 1755-1757; DOI: https://doi.org/10.1681/ASN.2014111157
Ian R. Barrows
*George Washington University School of Medicine, Washington, DC; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Ramezani
†Division of Renal Diseases and Hypertension, George Washington University, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominic S. Raj
†Division of Renal Diseases and Hypertension, George Washington University, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • acute renal failure
  • gut microbiome
  • short–chain fatty acids

In 1907, Elie Metchnikoff hypothesized that “autointoxication” by “putrefactive” bacteria accelerated aging and caused disease. Emerging science from the Human Microbiome Project and the Metagenomics of Human Intestinal Tract projects has brought in a paradigm shift in our perception about the gut microbiome.1 The human microbiome has coevolved with the host and established a symbiotic relationship, which has expanded our metabolic and biosynthetic capabilities well beyond what is coded in our genomes. Numbers of signaling molecules, receptors, and effectors from the microbiome that regulate host functions are being constantly unraveled.2 Short–chain fatty acids (SCFAs) are organic fatty acids with one to six carbons, which are products of bacterial fermentation of complex polysaccharides in the colon. The most abundant SCFAs are acetate, propionate, and bytyrate. SCFAs are shown to have physiologic functions and beneficial effects on the human host, but they are essentially waste products to the microbes, which are required to balance redox in the anaerobic environment of the colon.3 These molecules are partly metabolized by colonic epithelial cells, and a proportion enters the portal and peripheral circulation, where they exert their systemic effects through the G protein–coupled receptors, such as GPR41 and GPR43.

An observation that has intrigued researchers is that germfree mice have increased susceptibility to ischemia and reperfusion injury (IRI), which is reversed by colonization with commensal bacteria.4 The mechanism by which the gut microbiome confers protection against IRI is the focus of the study by Andrade-Oliveira et al.,5 which appears in this issue of JASN. In this exciting study, Andrade-Oliveira et al.5 have expanded the role of SCFAs beyond their well known role as nutrient for colonic epithelium and regulators of intracellular pH, ion transport, and cell proliferation to explain the gut-kidney connection in IRI. In a series of well designed in vivo and in vitro experiments, Andrade-Oliveira et al.5 show that treatment with SCFAs reduces IRI–induced kidney injury. Among the SCFAs, acetate treatment offered the best protection. Andrade-Oliveira et al.5 believe that the key mechanism that confers protection against AKI is reduction in inflammation mediated by an epigenetic mechanism. Andrade-Oliveira et al.5 also noticed an increase in autophagy, a reduction in apoptosis, and an improvement in mitochondrial biogenesis in response to treatment with SCFA. Furthermore, treatment with acetate-producing bacteria protected the mice kidneys from IRI.5 This study clearly shows that SCFA protects against IRI through convergence of multiple mechanisms, but it also provokes a number of questions.5 Considering the complexity of the communication between microbiome, cells, genes, and the ecosystem, it is often challenging to clearly define the role of individual components, which is the case in this study.

Inflammation plays a critical role in induction, maintenance, and resolution of AKI. Innate pattern recognition receptors, including Toll-like receptors (TLRs) and the inflammasome, trigger inflammation in response to tissue injury and pathogens.6 The composition of the microbiome influences the balance between immune regulatory (Treg) and proinflammatory (TH17) T cells. For instance, segmented filamentous bacterium residing in the terminal ileum in mice recruits CD4+ T helper cells that produce IL-17 and IL-22 (Th17 cells) in the lamina propria. Another commensal bacteria in the gut, Bacteroides fragilis, induces accumulation of Foxp3+ Treg cells. This effect was dependent on the expression of a capsular polysaccharide known as polysaccharide A by the bacteria.7 Smith et al.8 showed that feeding germfree mice with SCFAs, acetate, propionate, and butyrate increased the abundance of Foxp3+ Treg cells in the large intestine in a GPR43-dependent manner. Immune cells express the SCFA receptors GPR41 and GPR43.9 SCFAs may modulate the magnitude and direction of the immune responses by influencing the differentiation and proliferation of T cells and reducing proinflammatory cytokine expression initiated by TLR signaling.8 In the study by Andrade-Oliveira et al.,5 acetate treatment reduced inflammatory cell infiltration and expression of TLR-4 and its endogenous ligand, Biglycan. However, among the SCFAs, acetate is not the most potent activator of these receptors.9

Immune response is a highly coordinated multistep process that involves sequential epigenetic changes. Transition from euchromatin to transcriptionally silent heterochromatin is mediated by histone deacetylases (HDACs). Butyrate plays a role in modulating immune responses of intestinal macrophages by inhibiting HDAC, leading to a decreased production of proinflammatory mediators, such as NO, IL-6, and IL-12.10 HDAC also plays an important role in cell survival and cell proliferation. Recent studies have shown that a significant proportion of surviving, proliferating renal tubular epithelial cells undergo G2/M arrest after injury, which delays recovery from AKI. Hypermethylation of renin-angiotensin system protein activator like-1, which encodes renin-angiotensin system oncoprotein, perpetuates fibroblast activation and fibrogenesis in the kidney, and thus, it may lead to progressive loss of kidney function. In vitro studies have shown that butyrate regulates expression of genes that arrest growth and induces cellular differentiation.11 Furthermore, in the HT-29 carcinoma cell line, butyrate inhibited proliferation and increased apoptosis but had no effect on the normal epithelial cell line,12 suggesting that the action of SCFAs may depend on the state of activation of the target cells. Future studies should consider examining the effect of different SCFAs at different stages of IRI injury.

The hallmark of IRI is profound depletion of intracellular ATP content. In fact, adenine nucleotides infusion enhanced recovery from AKI after an ischemic insult. Mitochondria are the principal generators of cellular ATP. Two mechanistically distinct forms of programmed cell deaths (autophagy and apoptosis) may be induced by cellular stress. Mitochondria regulate the transition between apoptosis and autophagy, with low-intensity stress favoring autophagy and high intensity of cellular stress leading to apoptosis. Autophagy is an evolutionarily conserved cell survival mechanism that recycles cellular constituents to sustain bioenergetics. Jiang et al.13 showed that hypoxia induces autophagy in cultured renal proximal tubular cells. Blocking autophagy by 3-methyladenine or knockdown of autophagic genes (Becline-1 and ATG5) sensitized the cells to apoptosis. Providing butyrate or colonizing with butyrate-producing bacteria (Butyrivibrio fibrisolvens) improved oxidative phosphorylation and ATP synthesis and prevented autophagy.14 It is important to remember that autophagy is the lesser of two evils. The decrease in apoptosis and increase in autophagy observed in the study by Andrade-Oliveira et al.5 may be caused by improved mitochondrial energetics with acetate treatment. Although the increase in mitochondrial DNA content reported in the study provides some clue, future studies should be designed to examine mitochondrial function by assessing mitochondrial membrane potential, ATP content, and mitochondrial dynamics.5

The 2013 World Kidney Day Steering Committee focused on AKI: directing awareness to its effect and calling for campaigns to promote early detection, prevention, and implementation of evidence-based therapies. The study by Andrade-Oliveira et al.5 is very important in that it shows that SCFA confers kidney protection against IRI through multiple potentially biologically interrelated mechanisms. When analyzed critically, it seems that the common factor that underpins the kidney-protective effect of SCFA is through energy conservation in the oxygen-deprived kidney and by improvement of mitochondrial energetics. SCFAs provide about 10% of the daily caloric requirement in humans. They affect lipid, glucose, and cholesterol metabolism in various tissues. It is important to remember that mounting an immune response is an energy-consuming process, which may compete for meager energy resources in the setting of AKI. It is tempting to hypothesize that, other than providing an energy source to the kidney, SCFAs may be reducing the energy consumption by reducing inflammation, promoting apoptosis, and thereby, diverting the much-desired energy toward cellular regeneration.

Although the pioneering study by Andrade-Oliveira et al.5 is an important step in our comprehension of the effect of SCFAs on the ischemic kidney, it has left a number of questions to be addressed by future researchers. (1) Is the kidney-protective effect confined to acetate alone or applicable to other SCFAs as well? Convincing evidence indicates that propionate and butyrate are more effective than acetate in reducing inflammation and improving mitochondrial energetics, but then, why is acetate most effective in kidney IRI? (2) Do the signals from the ischemic kidney influence the generation of the amount and type of SCFAs produced by the gut microbiome? (3) Is there a mechanism by which the body traffics the SCFAs from the gut to the kidneys in IRI? (4) Does the kidney express specific receptors in response to IRI, or is it is solely through receptors present in the invading inflammatory cells? (5) Is there a role for the vascular effects of SCFAs mediated through Olfr78 and Gpr41 in protection against the IRI?15 Answering these questions will improve our understanding and propel the SCFAs to prime time in the management of AKI.

In this state of knowledge, it is important that we do not overemphasize the importance of a single metabolite without fully understanding how the modulations of these biologic effects interact to confer protection against a complex disease process, such as AKI. Although the results from the study are encouraging, caution must be exercised when in vitro and animal studies are extrapolated to human disease.

Disclosures

None.

Acknowledgments

D.S.R. was supported by National Institutes of Health Grants 1R01-DK073665-01A1, 1U01-DK099924-01, and 1U01-DK099914-01.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion,” on pages 1877–1888.

  • Copyright © 2015 by the American Society of Nephrology

References

  1. ↵
    1. Turnbaugh PJ,
    2. Ley RE,
    3. Hamady M,
    4. Fraser-Liggett CM,
    5. Knight R,
    6. Gordon JI
    : The human microbiome project. Nature 449: 804–810, 2007
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ramezani A,
    2. Raj DS
    : The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 25: 657–670, 2014
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Topping DL,
    2. Clifton PM
    : Short-chain fatty acids and human colonic function: Roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81: 1031–1064, 2001
    OpenUrlCrossRefPubMed
  4. ↵
    1. Jang HR,
    2. Gandolfo MT,
    3. Ko GJ,
    4. Satpute S,
    5. Racusen L,
    6. Rabb H
    : Early exposure to germs modifies kidney damage and inflammation after experimental ischemia-reperfusion injury. Am J Physiol Renal Physiol 297: F1457–F1465, 2009
    OpenUrlCrossRefPubMed
  5. ↵
    1. Andrade-Oliveira V,
    2. Amano MT,
    3. Correa-Costa M,
    4. Castoldi A,
    5. Felizardo RJF,
    6. de Almeida DC,
    7. Bassi EJ,
    8. Moraes-Vieira PM,
    9. Hiyane MI,
    10. Rodas ACD,
    11. Peron JPS,
    12. Aguiar CF,
    13. Reis MA,
    14. Ribeiro AR,
    15. Valguda CJ,
    16. Curi R,
    17. Vinolo MA,
    18. Ferreira CM,
    19. Câmara NOS
    : Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26: 1877–1888, 2015
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Wu H,
    2. Chen G,
    3. Wyburn KR,
    4. Yin J,
    5. Bertolino P,
    6. Eris JM,
    7. Alexander SI,
    8. Sharland AF,
    9. Chadban SJ
    : TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 117: 2847–2859, 2007
    OpenUrlCrossRefPubMed
  7. ↵
    1. Round JL,
    2. Mazmanian SK
    : Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107: 12204–12209, 2010
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Smith PM,
    2. Howitt MR,
    3. Panikov N,
    4. Michaud M,
    5. Gallini CA,
    6. Bohlooly-Y M,
    7. Glickman JN,
    8. Garrett WS
    : The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341: 569–573, 2013
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Le Poul E,
    2. Loison C,
    3. Struyf S,
    4. Springael JY,
    5. Lannoy V,
    6. Decobecq ME,
    7. Brezillon S,
    8. Dupriez V,
    9. Vassart G,
    10. Van Damme J,
    11. Parmentier M,
    12. Detheux M
    : Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278: 25481–25489, 2003
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Chang PV,
    2. Hao L,
    3. Offermanns S,
    4. Medzhitov R
    : The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 111: 2247–2252, 2014
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Davis T,
    2. Kennedy C,
    3. Chiew YE,
    4. Clarke CL,
    5. deFazio A
    : Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res 6: 4334–4342, 2000
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Bailón E,
    2. Cueto-Sola M,
    3. Utrilla P,
    4. Rodríguez-Cabezas ME,
    5. Garrido-Mesa N,
    6. Zarzuelo A,
    7. Xaus J,
    8. Gálvez J,
    9. Comalada M
    : Butyrate in vitro immune-modulatory effects might be mediated through a proliferation-related induction of apoptosis. Immunobiology 215: 863–873, 2010
    OpenUrlCrossRefPubMed
  13. ↵
    1. Jiang M,
    2. Liu K,
    3. Luo J,
    4. Dong Z
    : Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. Am J Pathol 176: 1181–1192, 2010
    OpenUrlCrossRefPubMed
  14. ↵
    1. Donohoe DR,
    2. Garge N,
    3. Zhang X,
    4. Sun W,
    5. O’Connell TM,
    6. Bunger MK,
    7. Bultman SJ
    : The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 13: 517–526, 2011
    OpenUrlCrossRefPubMed
  15. ↵
    1. Pluznick JL,
    2. Protzko RJ,
    3. Gevorgyan H,
    4. Peterlin Z,
    5. Sipos A,
    6. Han J,
    7. Brunet I,
    8. Wan LX,
    9. Rey F,
    10. Wang T,
    11. Firestein SJ,
    12. Yanagisawa M,
    13. Gordon JI,
    14. Eichmann A,
    15. Peti-Peterdi J,
    16. Caplan MJ
    : Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A 110: 4410–4415, 2013
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 26 (8)
Journal of the American Society of Nephrology
Vol. 26, Issue 8
August 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Gut Feeling in AKI: The Long Arm of Short–Chain Fatty Acids
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Gut Feeling in AKI: The Long Arm of Short–Chain Fatty Acids
Ian R. Barrows, Ali Ramezani, Dominic S. Raj
JASN Aug 2015, 26 (8) 1755-1757; DOI: 10.1681/ASN.2014111157

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Gut Feeling in AKI: The Long Arm of Short–Chain Fatty Acids
Ian R. Barrows, Ali Ramezani, Dominic S. Raj
JASN Aug 2015, 26 (8) 1755-1757; DOI: 10.1681/ASN.2014111157
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases
  • COVID-19–Associated Acute Kidney Injury: Learning from the First Wave
  • Will Targeting Interleukin-6 in the Anemia of CKD Change Our Treatment Paradigm?
Show more Up Front Matters

Editorials

  • Glomerular Exostosin Deposits in Membranous Lupus Nephritis—a Dialogue
  • The Road Ahead for Research on Air Pollution and Kidney Disease
  • Missing Self and DSA—Synergy of Two NK Cell Activation Pathways in Kidney Transplantation
Show more Editorials

Cited By...

  • Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease
  • Google Scholar

Similar Articles

Related Articles

  • Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion
  • PubMed
  • Google Scholar

Keywords

  • acute renal failure
  • gut microbiome
  • short–chain fatty acids

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire